Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan vs physician's choice chemotherapy in HR+/HER2- advanced breast cancer after endocrine therapy
jRCT2061230032Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Aug 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in breast cancer (2 arms), sponsored by Gilead Sciences. Primary endpoint: Progression-free survival by BICR (RECIST v1.1). Started Aug 2023; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2061230032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230032.